NOVEL ANHYDROUS AMORPHOUS FORMS OF MONTELUKAST SODIUM SALT

The present invention relates to novel anhydrous amorphous forms of [R-(E)-1-[[[l-[3-[2-[7-chloro-2-quinolinyl] ethenyl] phenyl]-3-[2-(1-hydroxy-l-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid alkali salts (Montelukast alkali salts) to processes for their preparation, to composi...

Full description

Saved in:
Bibliographic Details
Main Authors BUCHI, REDDY REGURI, VEERA, VENKATA, NAGA, CHANDRA, SEKHAR BULUSU, SATYANARAYANA BOLLIKONDA
Format Patent
LanguageEnglish
Published 02.09.2003
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to novel anhydrous amorphous forms of [R-(E)-1-[[[l-[3-[2-[7-chloro-2-quinolinyl] ethenyl] phenyl]-3-[2-(1-hydroxy-l-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid alkali salts (Montelukast alkali salts) to processes for their preparation, to compositions containing them and to methods of treatment using the same. Montelukast is a leukotriene antagonist, is useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agent. Montelukast is represented by the formula (I).
Bibliography:Application Number: AU20030209043